Actavis Generic OxyContin To Launch In 2014 Under Patent Settlement
This article was originally published in The Pink Sheet Daily
Actavis can sell a generic version of Purdue’s abuse-deterrent formulation 11 years before patents on the formulation expire; the company will launch on Jan. 1 if FDA approves its ANDA, or launch an authorized generic in October if approval is delayed.
You may also be interested in...
FDA reviewed all the categories of pre-marketing and post-marketing data outlined by guidance for abuse-deterrent opioids, but only in vitro and liking studies made it into the updated label.
Operation Warp Speed confirmed the necessity of having a facility on hand to develop and manufacture a vaccine for the next crisis, the outgoing advisor says.
Broader use of adaptive trial designs and master protocols, checklist-based application review, and enhancement of real-world monitoring of products are among the recommendations of US FDA's COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) report, an effort months in making based on interviews with agency management, staff, and outside stakeholders.